EP1343534A2 - Traitement du cancer avec des produits radiopharmaceutiques emettant des positrons - Google Patents

Traitement du cancer avec des produits radiopharmaceutiques emettant des positrons

Info

Publication number
EP1343534A2
EP1343534A2 EP01994229A EP01994229A EP1343534A2 EP 1343534 A2 EP1343534 A2 EP 1343534A2 EP 01994229 A EP01994229 A EP 01994229A EP 01994229 A EP01994229 A EP 01994229A EP 1343534 A2 EP1343534 A2 EP 1343534A2
Authority
EP
European Patent Office
Prior art keywords
positron
emitting compound
administered
subject
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01994229A
Other languages
German (de)
English (en)
Inventor
Alex Wah Hin Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2001/048193 external-priority patent/WO2002058741A2/fr
Publication of EP1343534A2 publication Critical patent/EP1343534A2/fr
Withdrawn legal-status Critical Current

Links

Definitions

  • TECHNICAL FIELD This invention relates to novel therapeutic uses of fluorine-18, fluorine-18 labeled compounds, and other isotopically-labeled pharmaceuticals and radiopharmaceuticals for treatment of human diseases, particularly for treatment of cancer.
  • PET Positron emission tomography
  • PET scanning operates by administration of a positron-emitting compound to the subject to be scanned. This compound then localizes in various tissues in the body. When the compound decays by positron emission, the emitted positron will encounter an electron. The resulting matter-antimatter annihilation event results in the production of a pair of photons of approximately 511 keV which are detected by the PET scanner (10).
  • the positron-emitting compound typically has a relatively short half-life, and must be produced as soon as possible prior to administration to the subject. Radioisotopes are generated at the treatment facility by cyclotron radiation, and can then be chemically incorporated into the compound for administration.
  • the fluorine-18 ( 18 F) isotope is a widely used radioisotope for incorporation into compounds for PET scanning, due to its relatively long half life of 110 minutes. This allows sufficient time for synthesis of the labeled compound, administration to the subject, and uptake by the tissues of interest.
  • Typical dosages of fluorine- 18 containing compounds for PET scanning range from 3 to 20 mCi per 50 kg of body weight.
  • FDG fluorodeoxyglucose
  • the current invention provides methods for treatment of disease using positron-emitting compounds.
  • the invention provides new methods for treating disease in subjects, particularly cancer and related diseases.
  • the invention provides a method of treating a disease in a subject, comprising administering a therapeutically effective amount of a positron-emitting compound to the subject.
  • the positron emitting compound can comprise one or more atoms of fluorine-18, carbon-11, nitrogen-13, or oxygen-15.
  • the positron-emitting compound comprises one or more atoms of fluorine- 18.
  • the positron-emitting compound is 18 F- fluorodeoxyglucose. In another embodiment, the 18 F-fluorodeoxyglucose is 18 F-2- fluoro-2-deoxyglucose. In yet another embodiment, the positron-emitting compound is F-fluorocholine. In a further embodiment, the positron-emitting compound is [methyl- 1 *C] choline. In one embodiment of the invention, the positron-emitting compound is administered to the subject in a dosage at least about 1.5 to 2 times that used for diagnostic purposes. In another embodiment, the positron-emitting compound is administered to the subject in the maximum dosage that the patient can tolerate.
  • the positron-emitting compound is administered in a dosage of about 30 to 100 mCi per 50 kg of body weight.
  • the dosage of the positron emitting compound is about 30 mCi per 50 kg of body weight.
  • the dosage is about 40 mCi per 50 kg of body weight.
  • the dosage is about 50 mCi per 50 kg of body weight.
  • the dosage is about 60 mCi per 50 kg of body weight.
  • the dosage is about 70 mCi per 50 kg of body weight.
  • the dosage is about 80 mCi per 50 kg of body weight.
  • the dosage is about 90 mCi per 50 kg of body weight.
  • the dosage is about 100 mCi per 50 kg of body weight.
  • the positron-emitting compound administered in the preceding dosages is F-fluorodeoxyglucose. In another embodiment, the positron-emitting compound administered in the preceding dosages is 18 F-2- fluoro-2-deoxyglucose.
  • the positron-emitting compound in another embodiment, can be administered in conjunction with any combination of immunotherapy, surgery, radiation therapy, or other chemotherapy to the subject at any stage in the treatment of the subject.
  • the positron-emitting compound is administered intravenously.
  • the positron-emitting compound can be administered in one or two dosages per day, for between two to ten days sequentially or non-sequentially over a two-week to three-week period.
  • the positron-emitting compound can be administered in one or two dosages per day, for between five to ten days sequentially or non-sequentially over a two-week to three-week period.
  • between five and ten dosages are administered on consecutive days. In another embodiment of the invention, between five and ten dosages are administered on non-consecutive days over a two-week to three-week period. In another embodiment of the invention, between five and ten dosages are administered on non -consecutive days over a two- week period.
  • the disease to be treated is cancer. In yet another embodiment, the disease is bone cancer.
  • the invention embraces a composition comprising a dosage of any of the compounds described herein that is at least 1.5 to 2 times as high as the dosage used for diagnostics applications.
  • the invention also embraces use of a medicament comprising any of the compounds described herein for the preparation of a medicament for therapeutic treatment of cancer.
  • the invention also embraces unit dosage preparations of the compounds for therapeutic treatment of cancer, in any of the dosages described herein as useful for therapeutic treatment of cancer.
  • Treating" a disease or pathology is defined as preventing, eliminating, reducing the severity of, mitigating, or preventing the further development or spread of a disease or pathology, or preventing, eliminating, reducing the severity of, mitigating, or preventing the further development of the symptoms of a disease or pathological state.
  • Treating" a subject, individual, or patient is defined as treating the disease afflicting the subject, individual, or patient.
  • a “therapeutically effective amount” of a compound is a dosage of that compound sufficient for preventing, eliminating, reducing the severity of, mitigating, or preventing the further development or spread of a disease or pathology, or preventing, eliminating, reducing the severity of, mitigating, or preventing the further development of the symptoms of a disease or pathological state.
  • subject or “subject” is meant a vertebrate, preferably a mammal, more preferably a human.
  • “Patient” refers to an individual or subject who has undergone, is undergoing, or will undergo treatment.
  • administration is meant introducing a compound into a subject.
  • the preferred route of administration of the compounds is intravenous.
  • any route of administration such as oral, topical, subcutaneous, peritoneal, intraarterial, inhalation, vaginal, rectal, nasal, introduction into the cerebrospinal fluid, or instillation into body compartments can be used.
  • the present invention relates to novel therapeutic uses of positron-emitting radiopharmaceuticals, such as fluorine-18 containing compounds, in human diseases.
  • the methods of the invention are particularly useful in the treatment of cancer and related diseases.
  • Compounds useful in the invention are those compounds incorporating radioisotopes which emit positrons. Radioisotopes which emit positrons include, but are not limited to, fluorine-18 (half -life of 110 minutes), carbon-11 (half-life of 20 minutes), nitrogen-13 (half-life of 10 minutes), and oxygen-15 (half-life of 2 minutes).
  • positron-emitting radioisotopes include, but are not limited to, proteins, such as monoclonal and polyclonal antibodies and enzymes; linear, cyclic, and branched peptides, including N-methylated peptides and peptides incorporating D-amino acids or non-naturally occurring amino acids; peptidomimetics, such as peptoids, peptide nucleic acids, and peptides where the peptide bond is reduced or otherwise stabilized against hydrolysis; amino acids, including the twenty amino acids encoded by the genetic code, and other naturally occurring amino acids and non- naturally occurring amino acids (including, but not limited to, peptide nucleic acids, D-amino acids, amino acid alcohols, acetylated amino acids, other acylated amino acids, amino acid esters, amino acid amides, beta-amino acids, peptide- nucleic acids, and the like); nucleic acids, including, but not limited to, DNA,
  • RNA nucleotides, nucleosides, nucleotide analogs and nucleoside analogs
  • carbohydrates including, but not limited to, glucose, deoxyglucose, fluorodeoxyglucose, 2-fluoro-2-deoxyglucose, fructose, sucrose, galactose, lactose, and the like
  • drugs such as chemotherapeutic agents
  • small organic molecules preferably with a molecular weight of less than 1000, more preferably with a molecular weight of less than 600, including, but not limited to, choline, fluorocholine, and acetylcholine
  • substrates for biochemical reactions occurring in the subject include, but not limited to, choline, fluorocholine, and acetylcholine.
  • a compound useful in the invention is F-fluorodeoxyglucose (referred to as fluoro-18 FDG, 18 F-FDG, or simply FDG).
  • FDG F-fluorodeoxyglucose
  • 18 F-FDG 18 F-FDG
  • 18 F-2-fluoro-2- deoxyglucose is used.
  • the synthesis of this compound has been published and is known to those of skill in the art.
  • the FDG is administered to the subject, preferably via intravenous injection. Following intravenous administration of FDG, most of the radiopharmaceutical is rapidly cleared from the circulation with a half-life of less than 1 minute, as it mixes within a large distribution space, although there are longer-term compartments with half lives of up to 1.5 hours.
  • the substrate is taken up predominantly by malignant tumor tissues, infectious tissues, the myocardium, and the brain.
  • concentration in other organs especially the spleen, liver, and kidneys, but significant uptake in these organs has not been observed in human studies (9).
  • Other compounds useful for the methods of the invention include fluorine-18 fluorocholine and [ n C methyl]choline.
  • the therapeutic dosage of FDG for use in the methods of the invention is at least 30 mCi per 50 kg of body weight per dose.
  • the therapeutic dosage is generally between 30 and 100 mCi per 50 kg of body weight.
  • other useful dosages are 30, 40, 50, 60, 70, 80, 90, and 100 mCi per 50 kg of body weight per dose.
  • the PET scan estimated dose equivalent is about 1 rem for normal tissues with fluoro-18 FDG at a dosage of 10 mCi.
  • the EDE would be 137.5 rems with a 1% uptake and up to
  • Toxicity to major organs will remain relatively low because of the large size of the heart and brain tissue relative to the tumor tissue.
  • the normal EDE of 2.2 rems will be increased to 33 rems after a therapeutic course with 5 fractions of 30 mCi of FDG. Brain and myocardial damage from one course of such treatment is thus estimated to be minimal. Care should be taken to adjust the dosage appropriately if the patient has previously received radiation treatment of those organs, in order to prevent significant damage.
  • the dose limit for any single organ is 50 rems yearly for a radiation worker (4). However, this figure can be relaxed if the procedure is for treatment purposes.
  • Toxicity to the brain can be further reduced by using other fluoro-18 labeled compounds, such as fluorine-18 fluorocholine (FCH).
  • FCH does not accumulate in normal brain tissue as readily as FDG, and has the additional advantage of achieving higher concentration in tumor tissues (1, 2, 3, 5).
  • [Methyl- 1 'C] choline can also be used in the methods of the invention.
  • the invention thus provides straightforward methods for delivering a therapeutic agent to malignant tissue, with resulting damage to the malignant tissue and minimal damage to healthy tissue.
  • the methods of the invention can be used either alone or in combination with traditional methods of cancer therapy such as radiation therapy, chemotherapy, immunotherapy, and surgery.
  • the invention thus provides useful procedures for the treatment of cancer and other diseases.
  • PET scans were performed. Progressive reduction of the standard uptake value was achieved after each treatment and after the definitive external beam irradiation.
  • FCH Fluorescence-Coupled Device

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur le fluor-18, les produits radiopharmaceutiques contenant le fluor-18 (FRP) et d'autres isotopes émettant des positrons ainsi que des produits radiopharmaceutiques ayant été utilisés à des fins de diagnostic dans la tomographie par émission de positrons (TEP). L'invention décrit l'utilisation thérapeutique desdits produits radiopharmaceutiques émettant des positrons dont les FRP entre autres, pour le traitement du cancer et des maladies associées au cancer. Les produits radiopharmaceutiques sont administrés selon des dosages considérablement plus élevés que ceux utilisés dans le cadre de l'imagerie diagnostique.
EP01994229A 2000-12-18 2001-12-11 Traitement du cancer avec des produits radiopharmaceutiques emettant des positrons Withdrawn EP1343534A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25667100P 2000-12-18 2000-12-18
US256671P 2000-12-18
PCT/US2001/048193 WO2002058741A2 (fr) 2000-12-18 2001-12-11 Traitement du cancer et d'autres maladies grace a l'administration de produits radiopharmaceutiques emettant des positrons

Publications (1)

Publication Number Publication Date
EP1343534A2 true EP1343534A2 (fr) 2003-09-17

Family

ID=27765869

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01994229A Withdrawn EP1343534A2 (fr) 2000-12-18 2001-12-11 Traitement du cancer avec des produits radiopharmaceutiques emettant des positrons

Country Status (3)

Country Link
EP (1) EP1343534A2 (fr)
AU (1) AU2002246651A1 (fr)
TW (1) TWI231215B (fr)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02058741A3 *

Also Published As

Publication number Publication date
AU2002246651A1 (en) 2002-08-06
TWI231215B (en) 2005-04-21

Similar Documents

Publication Publication Date Title
Krolicki et al. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue
Królicki et al. Dose escalation study of targeted alpha therapy with [225Ac] Ac-DOTA-substance P in recurrence glioblastoma–safety and efficacy
Larson et al. Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience.
ES2250419T3 (es) Radioterapia.
EP4473980A2 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement de cancers exprimant le psma
Kaim et al. 18F-FDG and 18F-FET uptake in experimental soft tissue infection
KR100219964B1 (ko) 방사성 약물의 제제,이들의 투여방법 및 제조방법
Santos-Cuevas et al. 177Lu‐DOTA‐HYNIC‐Lys (Nal)‐Urea‐Glu: biokinetics, dosimetry, and evaluation in patients with advanced prostate cancer
CN112843260A (zh) 一种医用放射性二氧化硅微球及其制备方法与应用
Wang et al. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer
Bruland et al. Radium-223: from radiochemical development to clinical applications in targeted cancer therapy
US20030021749A1 (en) Treatment of cancer and other diseases by administration of positron-emitting radiopharmaceuticals
Hassan et al. In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient
Elboga et al. An automated synthesis of 177 Lu-EDTMP as an efficient bone-seeking therapeutic radiopharmaceutical.
Liu et al. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model
Rottey et al. Influence of chemotherapy on the biodistribution of [^ sup 99m^ Tc] hydrazinonicotinamide annexin V in cancer patients
EP1343534A2 (fr) Traitement du cancer avec des produits radiopharmaceutiques emettant des positrons
Gilday et al. Evaluation of ytterbium-169 diethylenetriaminepentaacetic acid as a brain-scanning agent
JP3812680B2 (ja) 放射性医薬用途のペプチド類およびタンパク質類の安定化
Arista et al. Intralesional administration of I-131 labelled monoclonal antibodies in the treatment of malignant gliomas
JP2025503096A (ja) がんの処置および撮像のための複合体
Bundschuh et al. Enrico Michler1· David Kästner1· Marc Pretze1· Holger Hartmann1· Robert Freudenberg1· Michael K. Schultz2·
CA3234495A1 (fr) Polytherapie de complexe de radionucleides
Dos Santos Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy
JP7792746B2 (ja) 治療用骨剤の使用方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030501

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040324

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050701